Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

BA-321, a selective androgen receptor modulator for treatment of male osteoporosis

Sep. 22, 2014

Genzyme product receives orphan designation for Gaucher's disease

Sep. 22, 2014

FDA approves Trulicity for type 2 diabetes

Sep. 19, 2014

Bayer scientists report development of AKR1C3 inhibitors

Sep. 19, 2014

DPP IV inhibitors revealed in Hitgen patent

Sep. 19, 2014

MGAT2 inhibitors designed for effects on obesity and related disorders

Sep. 19, 2014

Selective blockade of PTH activity by stapled peptide ATSP-10814

Sep. 19, 2014

Empagliflozin/linagliptin FDC shows superior efficacy to individual components

Sep. 18, 2014

In vitro and in vivo bone anabolic effects of P2X7 receptor blocker AFC-5261

Sep. 18, 2014

Development of non-viral minicircle DNA vectors for phenylketonuria gene therapy

Sep. 18, 2014

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 8, 2026.
Hengrui discovers new Nav1.8 blockers
BioWorld Science
Researchers from Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have patented new sodium channel protein type 10 subunit α...
Hematopoietic stem cell research points to leukemia’s early roots
BioWorld Science
Hematopoietic stem cell (HSC) research over the past century has shown that leukemia may be driven by an invisible hand of inflammation. The bone marrow and...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 7, 2026
Infinimmune presents preclinical data on anti-IL-22 antibody for atopic dermatitis
BioWorld Science
Infinimmune Inc. has recently presented results at the annual American Academy of Dermatology conference regarding their anti-IL-22 antibody IFX-101 for the...